Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921576 | 0.81 | MEN1 (0.35) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL2499845 | 0.79 | MEN1 (0.37) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL6577360 | 0.79 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL3063253 | 0.76 | KDM4C (0.37) | — | |
| SCHEMBL15973939 | 0.75 | NPC1 (0.31) | HTT | |
| SCHEMBL17363422 | 0.74 | — | — | |
| SCHEMBL20524431 | 0.71 | LMNA (0.35) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL17641539 | 0.69 | MEN1 (0.34) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL117136 | 0.69 | HDAC4 (0.31) | — | |
| SCHEMBL4709766 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461816-B1 | FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-9371295-B2 | Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC | IRBM-SCIENCE PARK S.P.A. (IT) | 2016-06-21 | — | — | US | disclosed |
| US-20150218112-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-08-06 | — | — | US | disclosed |
| US-8604034-B2 | Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-10 | — | — | US | disclosed |
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2011-08-25 | — | — | US | disclosed |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | FURIN, SQOR, SUCNR1 | MEN1 2753/4885HTT 4509/4885KMT2A 3375/4885 |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | OPRL1, CNR1, TRPV1 | MEN1 4663/4885HTT 2516/4885KMT2A 3778/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | MEN1 2833/4885HTT 930/4885KMT2A 697/4885 |
| US-20150218112-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | HDAC5, HDAC4, HDAC6 | MEN1 3823/4885HTT 168/4885KMT2A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.